Cart
sales@molnova.com
BCL6-IN-6
CAS No. 2408882-54-0
BCL6-IN-6( —— )
Catalog No. M28485 CAS No. 2408882-54-0
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 152 | Get Quote |
|
| 5MG | 260 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | 1368 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBCL6-IN-6
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
-
DescriptionBCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorSARS-CoV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2408882-54-0
-
Formula Weight522.64
-
Molecular FormulaC27H31FN6O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 4 mg/mL (7.65 mM)
-
SMILESN(C1=NC(=NC=C1F)N2C[C@H](C)N[C@H](C)C2)C3=CC(OC)=C(NC(=O)C=4SC(=CC4)C=5CCCC5)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
BM-957
BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively.
-
A09-003
A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.
-
FX1
A potent, specific BCL6 BTB domain inhibitor with Kd of 7 uM, binds with a greater affinity than the natural BCL6 ligand SMRT (Kd=30 uM).
